Prostatic vibratory stimulation for refractory chronic prostatitis: A case report Authors: Leandro Reina Alcaina, Jesús Eugenio Rodríguez Martínez Published: 2026 ABSTRACT AbstractChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a challenging condition with limited effective treatments. We report a case of a 44-year-old man with refractory CP/CPPS treated with a home-based prostatic vibratory stimulation protocol. After 12 weeks, the NIH-CPSI score improved from 26 to 14, with marked reduction in pain and no adverse events. The patient reported subjective improvement on the Patient Global Impression of Improvement scale. This case suggests that targeted mechanical prostatic stimulation may represent a promising non-pharmacological option for selected patients. Introduction Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent and heterogeneous condition characterized by pelvic pain, urinary symptoms, and impaired quality of life.1,2 Despite its high prevalence, effective treatment options remain limited, particularly in patients with refractory symptoms.3 The pathophysiology of CP/CPPS is multifactorial, involving inflammatory, neuromuscular, and central sensitization mechanisms.4,5 Increasing attention has been directed toward non-pharmacological approaches, including pelvic floor rehabilitation and neuromodulation strategies.4,6 Mechanical prostatic stimulation represents a novel and largely unexplored therapeutic approach. This report describes the clinical evolution of a patient with refractory CP/CPPS treated with a targeted prostatic vibratory stimulation protocol. Case presentation A 44-year-old male presented with a long-standing history of chronic pelvic pain consistent with CP/CPPS. The patient reported persistent perineal discomfort, exacerbated during sitting and following ejaculation, along with urinary symptoms and reduced quality of life. Previous treatments included multiple pharmacological approaches, including alpha-blockers, anti-inflammatory drugs, and antibiotics, with limited or no sustained benefit. Pelvic floor physiotherapy had also been attempted without significant improvement. Baseline evaluation using the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) showed a total score of 26, with prominent pain symptoms (pain domain: 13) [Fig. 1]. Evolution of NIH-CPSI total score and pain domain before and after 12 weeks of prostatic vibratory stimulation. The patient was phenotyped according to the UPOINT system. Positive domains included psychosocial (chronic symptom-related distress and impact on quality of life) and organ-specific (perineal pain exacerbated by ejaculation). A tenderness component was also suspected based on symptom exacerbation during sitting, suggesting possible pelvic floor involvement. No evidence of infection was identified. Urinary symptoms were mild and not predominant, and no systemic neurologic features were present. The patient underwent a home-based intervention consisting of prostatic vibratory stimulation using a mechanical device (Molto™, MysteryVibe; frequency range: 70–110 Hz)[Fig. 2]. Mechanical vibratory device (Molto™, MysteryVibe) used for targeted prostatic stimulation. The selection of this device was informed by preliminary clinical observations suggesting a potential benefit of prostatic vibratory stimulation in patients with chronic non-bacterial prostatitis, as well as by its capacity to deliver targeted and controlled stimulation to the prostatic region. The protocol consisted of sessions lasting 2–5 minutes, performed on alternate days for a total duration of 12 weeks. The device was designed to deliver targeted mechanical stimulation to the prostate region during sexual activity. After 12 weeks of treatment, the NIH-CPSI total score decreased from 26 to 14, representing a clinically meaningful improvement. The reduction was particularly notable in the pain domain (from 13 to 7). No adverse events were reported during the intervention. Subjective improvement was assessed using the Patient Global Impression of Improvement (PGI-I), with the patient reporting being “somewhat better” (score: 3). Discussion CP/CPPS remains a therapeutic challenge due to its complex and multifactorial nature. Conventional treatments often provide limited relief, especially in patients with chronic or refractory symptoms.2,3 Emerging evidence suggests that neuromuscular dysfunction and pelvic floor hypertonicity play a key role in symptom generation.4,5 In this context, interventions targeting neuromodulation and muscle relaxation have gained increasing interest. Mechanical prostatic stimulation may act through several mechanisms. First, it may facilitate neuromodulation of afferent sensory pathways, potentially reducing pain perception. Second, it may contribute to the relaxation of pelvic floor musculature. Third, direct mechanical stimulation of the prostate may influence local vascularization and glandular drainage. This phenotypic profile (organ-specific and psychosocial domains) may help explain the observed response to a targeted neuromodulatory mechanical intervention. The use of vibratory stimulation in urological and sexual medicine contexts has been previously explored, particularly in ejaculatory disorders, but its application in CP/CPPS remains limited. Preliminary evidence supporting its use in this context has been reported in a small exploratory study, in which patients with long-standing refractory prostatitis showed reductions in pain and improvements in sexual function.7 Although limited by its small sample size and exploratory design, these findings provide an initial rationale for further investigation of this approach. This case further supports the potential role of targeted vibratory stimulation as a novel non-pharmacological strategy in selected patients. Importantly, the intervention was well tolerated, with no reported adverse effects, supporting its safety profile in this context. Although this report is limited to a single patient, the observed improvement in NIH-CPSI exceeds the threshold considered clinically meaningful. These findings are consistent with preliminary observations in additional patients and warrant further investigation in larger controlled studies. Conclusion Prostatic vibratory stimulation may represent a promising non-pharmacological approach for patients with refractory CP/CPPS. This case demonstrates clinically meaningful symptom improvement, particularly in pain, with good tolerability. Further studies are needed to confirm these findings and to better define patient selection criteria. CRediT authorship contribution statement Leandro Reina Alcaina: Project administration, Conceptualization. Jesús Eugenio Rodríguez Martínez: Writing – review & editing, Writing – original draft, Project administration, Methodology, Formal analysis, Data curation. Ethics approval and consent to participate The study was conducted in accordance with institutional and ethical standards. Written informed consent was obtained from the patient. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Declaration of generative AI and AI-assisted technologies No generative AI tools were used in the preparation of the scientific content of this manuscript. The authors take full responsibility for the content. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest The authors received the device (Molto™, MysteryVibe) for clinical evaluation. No financial compensation was received. The authors declare no other conflicts of interest. References